Class II
Ongoing
MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12.
Why: CGMP Deviations
- Company
- Baxter Healthcare Corporation
Deerfield, IL, United States - Reported
- Sep 9, 2026
- Recall started
- Aug 6, 2026
- Where sold
- US Nationwide; Puerto Rico; and Chile.
- Amount
- N/A
- Full product description
- MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12.
- Lots / codes affected
- Lot # NC188630, NC188708, NC188791, NC188845, NC188876, NC188968, Exp Date: 12/31/2027; Lot # NC193719, NC193849, Exp Date: 04/30/2028; Lot # NC194051, NC194105, Exp Date: 05/31/2028; Lot # NC195171, Exp Date: 06/30/2028.
Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.